Vanda Pharmaceuticals Inc. reported second quarter 2026 financial results, announcing total net product sales of $50.5 million and a net loss of $62.5 million, or $1.04 per diluted share. Fanapt net product sales increased 23% to $36.0 million, while HETLIOZ sales declined 66% to $5.6 million. The company reiterated its full-year 2026 total revenue guidance of $240 million to $290 million and reported cash reserves of $170.0 million as of June 30, 2026. Vanda operates in the biopharmaceutical industry, developing and commercializing innovative therapies for neurological and psychiatric disorders.